==== Front Indian J Endocrinol MetabIndian J Endocrinol MetabIJEMIndian Journal of Endocrinology and Metabolism2230-82102230-9500Medknow Publications & Media Pvt Ltd India IJEM-22-46610.4103/ijem.IJEM_23_18Original ArticleSerum Lipid and Leptin Concentrations in Patients with Sheehan Syndrome Mir Shahnaz A. Shah Tabinda Singh Hardeep Shabir Iram 1Laway Bashir A. 2Division of Internal Medicine and Endocrinology, Government Medical College, Srinagar, Jammu and Kashmir, India1 Department of Biochemistry, Government Medical College, Srinagar, Jammu and Kashmir, India2 Department of Endocrinology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, IndiaAddress for correspondence: Dr. Bashir A. Laway, Department of Endocrinology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India. E-mail: drlaway@gmail.comJul-Aug 2018 22 4 466 468 Copyright: © 2018 Indian Journal of Endocrinology and Metabolism2018This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.Background: Sheehan syndrome (SS) refers to the occurrence of hypopituitarism after parturition. Hypopituitary adults with growth hormone (GH) deficiency have abnormal body composition with increased fat mass. As leptin is secreted almost exclusively by fat cells and the circulating leptin level is proportional to total fat mass, it is expected that abnormal elevations of leptin concentrations are found in GH deficient hypopituitary patients. The present study was undertaken to evaluate the anthropometric, lipid and leptin levels in patients with SS. Materials and Methods: Thirty patients with SS and 30 age and body mass index (BMI) matched controls were part in this study. All patients were stable on conventional replacement therapy for at least 6 months before the study. The subjects underwent detail clinical, biochemical, and hormone analysis. Results: Patients with SS on conventional replacement therapy showed significantly higher mean triglyceride, total cholesterol, low density lipoprotein cholesterol and lower high density cholesterol concentrations. The leptin levels were significantly raised in the patients with SS on standard replacement therapy compared with controls. The difference was more marked in obese cases versus obese controls than in lean cases and controls (P = 0.001). Conclusion: SS, a cause of GH deficiency. Our study demonstrated that patients with SS have an abnormal lipid profile, and raised leptin levels as compared to age and BMI matched controls. Keywords: Leptinlipid profileSheehan syndrome ==== Body INTRODUCTION Sheehan syndrome (SS) refers to the occurrence of varying degrees of hypopituitarism after parturition.[1] Some degree of hypopituitarism has been reported in 32% of women with severe postpartum hemorrhage.[23] Hypopituitary adults with growth hormone (GH) deficiency have abnormal body composition with increased fat mass.[4] Patients with hypopituitarism (particularly women) receiving conventional replacement therapy have higher cardiovascular mortality and morbidity than the general population, although this has not been extensively studied in patients with SS.[5] The exact mechanism of increased vascular disease in hypopituitarism and the causal relationship to GH deficiency is still unclear.[6] However, changes in carbohydrate and lipid metabolism and body composition may likely play a major role.[7] Leptin, a hormone secreted exclusively by fat cells is proportional to total fat mass and increased leptin level has been found in GH deficient hypopituitary patients.[8] Apart from fat mass and gender, many hormones influence circulating leptin levels like testosterone, GH, glucocorticoids, insulin, and estrogens.[910111213] In GH deficient hypopituitary adults, GH therapy after 52 weeks of treatment, caused significant decrease in the percentage of fat and leptin.[14151617] Based on this background, the present study was conducted to evaluate the lipid and leptin levels in patients with SS. MATERIALS AND METHODS Over a period of 2 years, 30 SS patients who attended endocrine clinic of internal medicine department were enrolled in the present study. These patients were on follow-up and were on treatment for more than 6 months. In addition, 30 age and BMI matched controls were recruited from hospital staff and friends. A written well-informed consent was obtained from all patients and controls and the study was performed according to the Declaration of Helsinki, 1975. The diagnosis of SS was based on history of postpartum hemorrhage and/or failure of lactation and/or amenorrhea following last child birth, more than one anterior pituitary hormone deficiency and empty sella on MR imaging.[18] Fasting early morning (08:30 am) blood samples were collected for glucose, follicle-stimulating hormone (FSH), luteinizing hormone (LH), cortisol, thyroid stimulating hormone (TSH), total T4, prolactin (PRL), and GH. In addition, samples were also collected in separate vacutainers for biochemical assays like liver function tests and lipid profile. Statistical analysis Statistical analysis was done using SPSS Version 20.0 (SPSS Inc., Chicago, Illinois, USA). Continuous variables were expressed as mean ± SD, median, and interquartile range. categorical variables were summarized as percentages. Chi-square test or Fisher's exact test, whichever appropriate, was used for comparison of categorical variables. Graphically the data were presented by bar and pie diagrams. P value of less than 0.05 was considered statistically significant. RESULTS The mean age of patients and controls was 47.7 ± 4.47 years and 47.3 ± 4.34 years, respectively. The duration of treatment in cases ranged from 6 months to 8 years. Of the 30 SS subjects, 16 (53.33%) had a BMI in the normal range, that is, (18.5–22.9), 10 patients (33.33%) were overweight (BMI 23–24.9), and only 4 (13.3%) were obese (BMI of >25). The detail of the clinical profile is given in Table 1. At least one hormone deficiency was present in all of the patients and more than one hormone deficiency in 88.7% of patients. The details of the hormone profile in SS patients are given in Table 2. All patients had corticotrophin deficiency and were treated with prednisolone and hydrocortisone. The average dose of hydrocortisone equivalent was 20 mg with mean of 18 ± 4.1 mg. All patients had thyrotroph deficiency and were treated with thyroxine; the average dose was 88 ± 25.1 μg/day. Twenty-two (73.33%) of 30 cases had blood glucose less than 100 mg/dl, 7 (23.33%) had levels between 100 and 126 mg/dl, and only 1 (3.33%) patient had blood glucose level of >126 mg/dl. The details of the biochemical profile in these subjects are given in Table 3. Patients median T4 was 1.5 μg/dl (IQR 1.16–3.9), cortisol stimulated was 4.12 μg/dl (IQR 2.4–7.9). The leptin level in cases was in the range of 11.2–42.8 ng/ml. Statistically, significant difference of leptin level was observed in obese cases versus obese controls (33.15 ± 5.98 vs 28.06 ± 2.99, P = 0.0001). Obese patients also had higher leptin levels than nonobese patients (P < 0.001). Similar findings were observed for obese versus nonobese controls (P 0.050). Table 1 Clinical profile of patients with Sheehan syndrome Table 2 Basal thyroid and pituitary hormonal parameters Table 3 Biochemical profile in patients with Sheehan syndrome DISCUSSION SS classically refers to postpartum hypopituitarism due to pituitary necrosis occurring secondary to massive bleeding at or just after delivery.[1] Pituitary insufficiency in SS may manifest in the form of partial or complete hormone insufficiency.[19] Severe GH deficiency is an established feature of SS and GH deficiency is associated with abnormal body composition, altered lipid profile, reduced quality of life, and osteoporosis. Replacement with recombinant GH results in significant improvement in most of these altered parameters. Although severe GH deficiency is a well-established feature of SS, the effects of GH deficiency in these patients has not been extensively investigated. Our study also revealed that the SS patients on conventional replacement therapy had significantly higher mean triglyceride (234 vs 160 mg/dl; P < 0.001), total cholesterol (208 vs 183 mg/dl; P = 0.026), and LDL cholesterol (122 vs 87 mg/dl; P = 0.002) and lower HDL cholesterol concentrations (45 vs 57.3 mg/dl; P = 0.026). These findings were consistent with Bhat et al.[20] who found total cholesterol (5.21 ± 0.98 mg/dl vs 4.57 ± 0.88 mg/dl, P < 0.001), LDL-cholesterol (3.15 ± 0.90 mg/dl vs 2.67 ± 0.75 mg/dl; P = 0.02), and triglycerides (2.14 ± 1.00 mg/dl vs 1.43 ± 0.45 mg/dl; P = 0.00) were significantly higher in patients with SS. Ozbeyet al.[21] studied serum lipid and leptin concentrations in hypopituitary patients with GH deficiency. Hypopituitary patients with GH deficiency on conventional replacement therapy showed significantly higher TG, LDL cholesterol, and lower HDL cholesterol concentrations. Bohdanowicz-Pawlak et al.[22] also observed that the HDL cholesterol level was lower and TG level higher in hypopituitary patients than in controls. Serum concentrations of total cholesterol in both GH deficient patients and controls were not significantly different. The level of LDL cholesterol was significantly higher in GH deficient women, whereas in men the difference was not statistically significant. Similar findings were reported by Hagmar et al.[23] who reported that in untreated GH-deficient adults, levels of total cholesterol, LDL cholesterol, triglycerides, and apolipoprotein B were increased, and HDL-cholesterol level was reduced compared with those in healthy adults. Tanriverdi et al.[24] also reported that at baseline, mean total cholesterol, LDL-cholesterol, and triglyceride levels were higher than the normal reference ranges but HDL-cholesterol levels were within the lower normal range. In the present study, it was observed that the leptin levels were significantly higher in the cases with a mean ± of 24.7 ± 7.46 ng/ml compared to controls (14.9 ± 3.76 ng/ml). This difference was statistically significant (P ≤ 0.001). The difference was more marked in obese cases versus obese controls than in lean cases and controls. Obese patients also had higher leptin levels than nonobese patients. Similar findings were observed for obese versus nonobese controls. Ozbey et al.[21] also found significantly higher leptin concentrations in patients with hypopituitarism compared with healthy controls with similar body fat content (23.5 + 11.8 ng/ml vs 11.7 + 6.9 ng/ml, P = 0.01). This difference remained significant even when leptin values were expressed in relation to fat mass percentage. CONCLUSION Patients with SS have an abnormal lipid profile, and raised leptin levels as compared to age and BMI matched controls. Whether this is a result of the adverse effects of GH deficiency on body composition needs to be elucidated. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest. ==== Refs REFERENCES 1 Kelestimur F Sheehan's syndrome Pituitary 2003 6 181 8 15237929 2 Laway BA Mir SA Gojwari T Shah TR Zargar AH Selective preservation of anterior pituitary functions in patients with Sheehan's syndrome Indian J Endocrinol Metab 2011 15 Suppl 3 S238 41 3 Bulow B Hagmar L Mikoczy Z Nordstrom CH Increased cerebrovascular mortality in patients with hypopituitarism Clin Endocrinol 1997 46 75 81 4 Abdu TA Neary R Elhadd TA Akber M Clayton RN Coronary risk in growth hormone deficient hypopituitary adults: Increased predicted risk is due largely to lipid profile abnormalities Clin Endocrinol (Oxf) 2001 55 209 16 11531927 5 Rosen T Premature mortality due to cardiovascular disease in hypopituitarism Lancet 1990 336 285 8 1973979 6 Evans LM Davies JS Goodfellow J Rees JA Scanion MF Endothelial dysfunction in hypopituitary adults with growth hormone deficiency Clin Endocrinol (Oxf) 1999 50 457 64 10468904 7 Shahi M Beshyah SA Hackett D Sharp P Johnston DG Foale RA Myocardial function in treated adult hypopituitarism: A possible explanation for increased cardiovascular mortality Br Heart J 1992 67 92 6 1739534 8 Li ZP Zhang M Gao J Zhou GY Li SQ An ZM Study of the correlation between growth hormone deficiency and serum leptin, adiponectin, and visfatin levels in adults Genet Mol Res 2014 13 4050 6 24615119 9 Behre H Simoni M Strong association between serum levels of leptin and testosterone in men Clin Endocrinol (Oxf) 1997 47 237 40 9302400 10 Miyakawa M Tsushima T Murakami H Osizaki O Demura H Effect of growth hormone (GH) on serum concentrations of leptin: Study in patients with acromegaly and GH deficiency J Clin Endocrinol Metab 1998 83 3476 9 9768649 11 Papaspyrou Rao S Schneider S Petersen R Fried SK Dexamethasone increases leptin expression in humans in vitro J Clin Endocrinol Metab 1997 82 1635 7 9141563 12 Boden G Chen X Kolanczynski J Effects of prolonged hyperinsulinemia on serum leptin in normal human subjects J Clin Invest 1997 10 1107 13 13 Shimizu H Shiommura Y Nakanishi Y Futawatari T Ohtani K Sato N Estrogen increase in vivo leptin production in rats and human subjects J Endocrinol 1997 154 285 92 9291839 14 Fisker S Vahl N Hansen T Jorgensen J Hagen C Orskov H Serum leptin is increased in growth hormone-deficient adults: Relationship to body composition and effects of placebo-controlled growth hormone therapy for 1 year Metabolism 1997 46 812 7 9225837 15 Brennan B Rahim A Blum W Adams JA Eden OB Shalet SM Hyperleptinemia in young adults following cranial irradiation in childhood: Growth hormone deficiency or leptin insensitivity? Clin Endocrinol (Oxf) 1999 50 163 9 10396357 16 Farooqi IS Jebb SA Langmack G Lawrence E Cheetham CH Prentice AM Effects of recombinant leptin therapy in a child with congenital leptin deficiency N Engl J Med 1999 341 879 84 10486419 17 Kristensen K Pedersen S Fisker S Norrelund H Rosenfalck A Jorgensen J Serum leptin levels and leptin expression in growth hormone (GH)-deficient and healthy subjects: Influence of GH treatment, gender and fasting Metabolism 1998 47 1514 9 9867083 18 Karaca Z Laway BA Dokmetas HS Atmaca H Kelestimur F Sheehan syndrome Nat Rev Dis Primers 2016 2 1 14 19 Haddock L Vega LA Aguiló F Rodríguez O Adrenocortical, thyroidal and human growth hormone reserve in Sheehan's syndrome Johns Hopkins Med J 1972 131 80 99 4115139 20 Bhat MA Laway BA Shah ZA Wani AI Insulin resistance, metabolic syndrome and chronic low grade inflammation in Sheehan's syndrome on standard replacement therapy: A case control study Pituitary 2015 18 312 8 24879499 21 Ozbey N Algun E Turgut AS Orhan Y Sencer E Molvalilar S Serum lipid and leptin concentrations in hypopituitary patients with growth hormone deficiency Int J ObesRelatMetabDisord 2000 24 619 26 22 Bohdanowicz-Pawlak A Szymczak J Bladowska J Bednarek-Tupikowska G Bidzińska B Milewicz A Risk factors of cardiovascular disease in GH-deficient adults with hypopituitarism: A preliminary report Med Sci Monit 2006 12 75 80 23 Bulow B Hagmar L Mikoczy Z Nordstrom CH Erfurth EM Increased cerebrovascular mortality in patients with hypopituitarism Clin Endocrinol 1997 46 75 81 24 Tanriverdi F Unluhizarci K Kula M Guven M Bayram F Kelestimur F Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome Growth Horm IGF Res 2005 15 231 7 15921942